Immunoglobulin therapy in bone marrow transplantation.

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Bone marrow transplantation (BMT) recipients often experience immunologic deficiencies post-transplant.
• Chronic graft-versus-host disease (GVHD) is associated with persistent B and T cell abnormalities and impaired immunoglobulin function.
• Immunoglobulin replacement therapy is explored to address these immunodeficiencies.

Purpose of the Study:

• To review clinical trials evaluating the efficacy of immunoglobulin therapy in preventing infections and complications after bone marrow transplantation.
• To assess the impact of immunoglobulin therapy on outcomes such as cytomegalovirus infection, interstitial pneumonia, and graft-versus-host disease.

Main Methods:

• Systematic review of 12 published clinical trials on immunoglobulin therapy in bone marrow transplant recipients.
• Analysis of controlled studies focusing on infection rates (cytomegalovirus, interstitial pneumonia) and GVHD incidence.
• Examination of data from randomized trials assessing GVHD and septicemia rates.

Main Results:

• Controlled studies showed reduced rates of cytomegalovirus infection (30% vs. 43%) and interstitial pneumonia (17% vs. 43%) in immunoglobulin recipients compared to controls.
• Three randomized trials indicated a potential decrease in GVHD or post-engraftment septicemia with immunoglobulin therapy.
• Significant variability existed in immunoglobulin preparation, dosage, and patient/transplant factors across studies.

Conclusions:

• Immunoglobulin therapy shows promise in reducing infections and potentially GVHD in bone marrow transplant patients.
• Variations in study methodologies necessitate cautious interpretation of current data.
• Ongoing controlled trials are crucial to definitively establish the role and optimal use of immunoglobulin therapy in this patient population.